<SEC-DOCUMENT>0001376339-21-000095.txt : 20210803
<SEC-HEADER>0001376339-21-000095.hdr.sgml : 20210803
<ACCEPTANCE-DATETIME>20210803172654
ACCESSION NUMBER:		0001376339-21-000095
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210803
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210803
DATE AS OF CHANGE:		20210803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIMEDX GROUP, INC.
		CENTRAL INDEX KEY:			0001376339
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				262792552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35887
		FILM NUMBER:		211141188

	BUSINESS ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062
		BUSINESS PHONE:		(770) 651-9100

	MAIL ADDRESS:	
		STREET 1:		1775 W OAK COMMONS COURT, NE
		CITY:			MARIETTA
		STATE:			GA
		ZIP:			30062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alynx, Co.
		DATE OF NAME CHANGE:	20060922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mdxg-20210803.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:6a9cdaba-539b-4768-8d5e-c492b3a0428b,g:0f138a66-3c41-4a4d-a286-37b9255723ba,d:019d6cfc389c4cf3b1929a2eaede7f67--><html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mdxg-20210803</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N180L2ZyYWc6YjQ0MGNiNmQzN2QzNDY1MDhkNTRiZjJmZmUxMDE0YmEvdGFibGU6Y2E4Mzc5MWYyOGE3NGFiNWJmYTY1MzhkNzI2MGUxNmYvdGFibGVyYW5nZTpjYTgzNzkxZjI4YTc0YWI1YmZhNjUzOGQ3MjYwZTE2Zl8yLTEtMS0xLTA_edc3964c-9475-41d5-8ae7-dead79b9d7bd">0001376339</ix:nonNumeric><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N180L2ZyYWc6YjQ0MGNiNmQzN2QzNDY1MDhkNTRiZjJmZmUxMDE0YmEvdGFibGU6Y2E4Mzc5MWYyOGE3NGFiNWJmYTY1MzhkNzI2MGUxNmYvdGFibGVyYW5nZTpjYTgzNzkxZjI4YTc0YWI1YmZhNjUzOGQ3MjYwZTE2Zl80LTEtMS0xLTA_c49f3310-c943-45b0-8c87-3c3549b23b7e">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mdxg-20210803.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001376339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-03</xbrli:startDate><xbrli:endDate>2021-08-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i019d6cfc389c4cf3b1929a2eaede7f67_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkx_73bb1c1b-e4de-4f5d-996a-5eb0c44d276c">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl8yNjY_010548d7-ba6e-48ce-ae41-21374672879f">August 3, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDky_7f572413-0523-48f3-ac5a-c4b2cbfbe926">MIMEDX GROUP, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.539%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTAtMS0xLTA_d5afe9d5-d07b-43c1-b5c0-75f032fdb24b">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTItMS0xLTA_e1fe21ae-48c9-4ba8-980d-4a5fe94199ff">001-35887</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTQtMS0xLTA_aac5f528-cc41-497b-86dc-a27c18e4ff45">26-2792552</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkz_a2c83742-9542-4cb0-a8d5-752cec542897">1775 West Oak Commons Ct., NE</ix:nonNumeric>, <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk0_f47252cc-cc85-49dd-8c13-e3c279a0c5d3">Marietta</ix:nonNumeric> <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk1_d91af8b0-dfd8-4403-8f66-8175854f754f">GA</ix:nonNumeric> <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk2_4950b0fa-5422-4845-875d-550248d22072">30062</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk3_a7df9d3f-8e34-40cb-9219-3bbff4c70848">770</ix:nonNumeric>) <ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk4_2e765f91-7713-41fd-a74d-77c488d11e21">651-9100</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:0.1%"></td><td style="width:2.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18wLTAtMS0xLTA_4821b00f-ddcc-40b7-a49d-d42678786f45">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18xLTAtMS0xLTA_e9ea04ae-6507-4eae-824c-cb0c12782014">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18yLTAtMS0xLTA_8ba905f4-ed73-47f5-bdd9-2f4fadd5a0a6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18zLTAtMS0xLTA_c4442e03-b4f0-4170-ba26-12a446b9192a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.350%"><tr><td style="width:1.0%"></td><td style="width:27.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTAtMS0xLTA_e9e2d84c-6f36-4dcc-803a-333acfc8d647">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTItMS0xLTA_aee54f97-3394-4b8a-ba97-b75896e37427">MDXG</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTQtMS0xLTA_56226558-229c-4708-a1df-ceb04b331dfa">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkw_f3aaabb2-0ec0-4851-a083-d56a682e01d4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Important Cautionary Statement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Important Cautionary Statement </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This report includes forward-looking statements. Statements regarding: (i) future sales or sales growth; (ii) the status, timing, and expected results of the Company&#8217;s clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission and eventual BLA approvals; (iii) the timing of our disclosure of clinical trial results; (iv) the results of future scientific studies; (v) expectations regarding our ability to sell EPIFIX in other countries, (vi) the effectiveness of amniotic tissue as a therapy for any particular indication or condition, and (vii) future increases in research and development spending. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," &#8220;goal,&#8221; &#8220;outlook,&#8221; "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors; (ii) the status, timing, and expected results of the Company&#8217;s clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission, depend on a number of factors including favorable trial results, patient access, and our ability to manufacture in accordance with CGMP and appropriate chemistry and manufacturing controls; (iii) the Company may change its plans due to unforeseen circumstances, or delays in analyzing and auditing results, and may delay or alter the timeline for future trials, analyses, or public announcements; (iv) the results of scientific research are uncertain and may have little or no value; (v) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (vi) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; and (vii) we may alter the timing and amount of planned expenditures for research and development based on the results of clinical trials and other regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this report and the Company assumes no obligation to update any forward-looking statement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02 Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, MiMedx Group Inc., (the &#8220;Company&#8221;) issued a press release (the &#8220;10-Q Press Release&#8221;) announcing the filing of its quarterly report on Form 10-Q for the period ended June 30, 2021. The 10-Q Press Release also includes certain information regarding the Company&#8217;s financial results for the period ended June 30, 2021. A copy of the 10-Q Press Release is attached hereto as Exhibit 99.1 and is incorporated herein for reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing information is furnished pursuant to Item 2.02, &#8220;Results of Operations and Financial Condition.&#8221; Consequently, it is not deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K. All information in the news release speaks as of the date thereof and the Registrant does not assume any obligation to update said information in the future. In addition, the Registrant disclaims any inference regarding the materiality of such information which otherwise may arise as a result of its furnishing such information under Item 2.02 of this report on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210803mdxg2q2021pressre.htm">Press Release </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210803mdxg2q2021pressre.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a20210803mdxg2q2021pressre.htm">ugust 3, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span><br/></span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MIMEDX GROUP, INC.</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 3, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter M. Carlson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Carlson<br/>Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20210803mdxg2q2021pressre.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7458bebc7136487281e140ca8a2407da_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%">EXHIBIT 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MIMEDX Announces Second Quarter 2021 </font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:133%">Operating and Financial Results</font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Second Quarter Net Sales Increase 27% to $68.2 million Versus Q2 2020</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">On Track to Deliver Topline Results for Late-Stage Musculoskeletal Pipeline in Late Summer</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Company to Host Conference Call on August 4, 2021, at 8&#58;30 AM ET </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">MARIETTA, Ga., August 3, 2021</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> -- MiMedx Group, Inc. (Nasdaq&#58; MDXG) (&#8220;MIMEDX&#8221; or the &#8220;Company&#8221;), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the filing of its second quarter 2021 Form 10-Q for the period ended June 30, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Timothy R. Wright, MIMEDX Chief Executive Officer, commented, &#8220;Our expanded commercial team is working aggressively toward the goal of achieving above-market growth for our Advanced Wound Care business, and executing on multiple initiatives that reinforce the differentiation of our products and convey the clinical and economic value of our brands. As the only data-driven amniotic tissue allograft to have complete national commercial coverage for the treatment of Diabetic Foot Ulcers, we continue to leverage our expansive reimbursement coverage and invest in medical education programs that are designed to raise awareness on the appropriate and timely use of our Advanced Wound Care products. It is imperative that we continue to grow this base business to support patients in need.&#8221;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Mr. Wright continued, &#8220;I applaud the team for their efforts to exercise strong leadership and exceptional customer service throughout the end of the period of Enforcement Discretion. Our proactive and continued dialogue with the U.S. Food and Drug Administration (FDA) enabled us to mitigate customer disruption, dispel misinformation, and partner with customers throughout the transition. Backed by years of clinical, tissue engineering, and manufacturing knowledge about the science of amniotic tissue, MIMEDX is well-positioned to advance into a more rigorously regulated biologics pathway, and we are making significant progress on the critical steps necessary for a complete and potentially successful Biologics License Application (BLA). We remain on track to share topline results for our Plantar Fasciitis and Knee Osteoarthritis programs by late summer and review these data with the FDA.&#34; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Second Quarter 2021 and Recent Operating Highlights&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM) to develop and advance scientific evidence in support of safe and effective clinical therapies</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Received regulatory approval to commercialize PURION&#174; processed EPIFIX&#174; in Japan</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Announced the publication of a peer-reviewed study in the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Journal of Investigative Dermatology Innovations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> addressing the potential benefit of MIMEDX PURION&#174; processed dehydrated Human Amnion&#47;Chorion Membrane (dHACM) to combat complications stemming from excessive fibrosis, a pathological process central to a number of serious unmet medical needs</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Added to the Russell 2000&#174; and Russell 3000&#174; Indexes </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Notified by the FDA that the Company's Investigational New Drug (IND) for the use of AMNIOFIX&#174; Injectable (mdHACM) in Surgical Incisions was accepted as filed</font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Expanded sales force headcount by ten percent </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">MIMEDX Board member Cato T. Laurencin, M.D., Ph.D. awarded the NAACP's highest honor for his contributions to emerging medical sciences that advance human healing</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Key Second Quarter 2021 Financial Metrics</font></div><div><font><br></font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Net sales of $68.2 million for second quarter 2021, compared to $53.6 million for the year prior</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Adjusted net sales</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">, which excludes impacts of the change in the Company&#8217;s methods for recognizing revenue, of $67.9 million for second quarter 2021, compared to $51.9 million for the prior year period</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Net loss of $1.8 million for second quarter 2021, compared to a net loss of $8.5 million for the prior year period</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:12.53pt">Adjusted EBITDA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> of $2.8 million for second quarter 2021, compared to $10.2 million for the prior year period</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,165&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,647&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,132&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,383&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Adjusted net sales</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:145%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,852&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,941&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,521&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,182&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,779)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,466)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,161)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,287)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">EBITDA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:145%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,108&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,172)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,343)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,133)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Adjusted EBITDA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:145%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,837&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,241&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,570&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,355&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share - basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.03)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.08)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.12)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.12)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share - diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.03)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.08)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.12)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.12)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:133%;padding-left:11.94pt">Adjusted Net Sales is a non-GAAP financial measure. See &#8220;Reconciliation of GAAP Net Sales to Adjusted Net Sales and Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA&#8221; for a reconciliation of Adjusted Net Sales to Net Sales, located in &#8220;Selected Unaudited Financial Information&#8221; of this release.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:133%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:133%;padding-left:11.94pt">EBITDA and Adjusted EBITDA are non-GAAP financial measures. See &#8220;Reconciliation of GAAP Net Sales to Adjusted Net Sales and Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA&#8221; for a reconciliation of EBITDA and Adjusted EBITDA to Net loss, located in &#8220;Selected Unaudited Financial Information&#8221; of this release.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">MIMEDX reported net sales for the three months ended June 30, 2021, of $68.2 million, a $14.6 million increase compared to the three months ended June 30, 2020, in which the Company reported revenue of $53.6 million. Net sales for the three months ended June 30, 2021, includes revenue recognized on the remaining contracts of $0.3 million, compared to $1.7 million for the three months ended June 30, 2020.  </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Adjusted net sales for the three months ended June 30, 2021, which excludes cash collected on the remaining contracts outstanding at the time of the change in the Company's revenue recognition methodology, were $67.9&#160;million compared to $51.9&#160;million for the three months ended June 30, 2020, an increase of 30.6%. The increase was primarily the result of an increase in sales volume over the prior year period, which was previously impacted by the COVID-19 pandemic. Sales from EPICORD&#174; Expandable, which the Company launched in the second half of 2020, growth in the flagship EPIFIX&#174; </font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">sheet portfolio, and sales of Section 351 products prior to the end of Enforcement Discretion contributed to the year-over-year increase in net sales.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">MIMEDX has two primary classes of products&#58; (1) Advanced Wound Care, or Section 361, products, consisting of its sheet allograft products, and (2) Section 351 products, consisting of the Company&#8217;s micronized and particulate products. Advanced Wound Care is further disaggregated between the Company&#8217;s Tissue&#47;Other and Cord products. A summary of the Company's revenue, including revenue derived from its Section 351 products, is included in the table below (amounts in thousands)&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.881%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.881%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.881%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advanced Wound Care</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tissue&#47;Other</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,408&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,528&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,977&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,134&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cord</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,886&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,263&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,846&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,160&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Advanced Wound Care</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,294&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,791&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110,823&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,294&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 351</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,558&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,150&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,698&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,888&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Other</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:145%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,706&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">611&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,201&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,165&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,647&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,132&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,383&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.1pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:145%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:145%;padding-left:11.94pt">&#8220;Other&#8221; represents cash collections on the Remaining Contracts. Remaining Contracts are those contracts for which performance obligations have been satisfied as of September 30, 2019, but for which the criteria required for revenue recognition had not been met and would not be met until the ultimate collection of cash. For all practicable purposes, the Company is not able to allocate these revenues to different product groups.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gross profit margin for the three months ended June 30, 2021, was 81.3% compared to 84.7% for the three months ended June 30, 2020. The decrease in gross profit margin was primarily due to reserves recorded during the three months ended June 30, 2021, specifically related to Section 351 products, resulting from the end of the FDA's Enforcement Discretion period. Additionally, negative production variances from lower than planned production volumes affected gross profit margin.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Selling, general and administrative expenses for the three months ended June 30, 2021, increased $16.3 million, or 43.6%, to $53.6 million, compared to $37.3 million for the three months ended June 30, 2020. The increase in selling, general and administrative expenses during the current period reflects the restoration of full-salary levels and merit increases that were previously restricted during the prior period, along with significantly reduced travel costs in the midst of the COVID-19 pandemic. The Company also saw consulting and advisory expenses rise year-over-year, including $3.8 million related to the proxy contest during the second quarter 2021. Furthermore, the increase in selling, general and administrative expense was driven by year-over-year increases in commission expenses resulting from the increases in sales volume.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Research and development expenses were $4.1 million for the three months ended June 30, 2021, compared to $2.3 million for the three months ended June 30, 2020. The increase reflects higher consulting fees, increases in personnel costs, and additional head-count to support the Company's clinical research efforts. In addition, the Company, as planned, increased its investments in preclinical studies, supportive of current and potential clinical study indications. MIMEDX expects these costs to increase over time as the Company commences new clinical trials and continues working toward the </font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">filing of BLAs. The amount and timing of these expenses are partially dependent on whether interim results from MIMEDX's ongoing IND clinical trials merit further investment. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Investigation, restatement and related expenses for the three months ended June 30, 2021, was a benefit of $2.1 million compared to an expense of $11.4 million for the three months ended June 30, 2020. The benefit incurred during the three months ended June 30, 2021, reflects funds received from certain director and officer insurance policies, as well as negotiated reductions in previously recognized legal expenses advanced on behalf of certain former members of management. While MIMEDX expects to continue to incur some litigation costs moving forward, the Company anticipates continued reduction in investigation, restatement and related expenses, other than costs related to resolution of the securities class action matter, the amount and timing of which are highly uncertain. For additional details, see Note 12, &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">Commitments and Contingencies,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221; in the Unaudited Condensed Consolidated Financial Statements on Form 10-Q.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Net loss for the three months ended June 30, 2021, was $1.8 million compared to a net loss of $8.5 million for the three months ended June 30, 2020. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Adjusted EBITDA for the three months ended June 30, 2021, was $2.8 million, or 4.2% of adjusted net sales, compared to $10.2 million, or 19.7% of adjusted net sales, for the three months ended June 30, 2020.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">As of June&#160;30, 2021, the Company had $85.0 million of cash and cash equivalents, compared to $95.8 million as of December 31, 2020.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Enforcement Discretion</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">In November 2017, the FDA developed the regenerative medicine policy framework to support innovations in regenerative medicine therapies, including human cells, tissues, and cellular and tissue-based products (HCT&#47;Ps). As a result of the COVID-19 public health emergency, the FDA extended the Enforcement Discretion policy for certain HCT&#47;Ps that do not raise reported safety concerns or potential significant safety concerns, from November 2020 to May 31, 2021. On April 21, 2021, the FDA reaffirmed that the period of Enforcement Discretion would not be extended and would therefore end on May 31, 2021.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Outlook for 2021</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company expects that adjusted net sales for 2021 will be consistent with the prior year. This reflects the end of the period of Enforcement Discretion on May 31, 2021, and is in line with the expected impact previously disclosed in the Company&#8217;s 2021 Outlook, within the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Conference Call and Webcast</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">MIMEDX will host a conference call and webcast to review its second quarter 2021 results on Wednesday, August 4, 2021, beginning at 8&#58;30 am, Eastern Time. The call can be accessed using the following information&#58;</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Webcast&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">https&#58;&#47;&#47;edge.media-server.com&#47;mmc&#47;p&#47;2gfy7rx3</font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">U.S. Investors&#58; 877-359-9508</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">International Investors&#58; 224-357-2393</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Conference ID&#58; 8777681</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">A replay of the webcast will be available for approximately thirty days on the Company&#8217;s website at www.mimedx.com following the conclusion of the event.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Important Cautionary Statement </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">This press release includes forward-looking statements. Statements regarding&#58; (i) future sales or sales growth&#59; (ii) the status, timing, and expected results of the Company&#8217;s clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission and eventual BLA approvals&#59; (iii) the timing of our disclosure of clinical trial results&#59; (iv) the results of future scientific studies&#59; (v) expectations regarding our ability to sell EPIFIX in other countries, (vi) the effectiveness of amniotic tissue as a therapy for any particular indication or condition, and (vii) future increases in research and development spending. Additional forward-looking statements may be identified by words such as &#34;believe,&#34; &#34;expect,&#34; &#34;may,&#34; &#34;plan,&#34; &#8220;goal,&#8221; &#8220;outlook,&#8221; &#34;potential,&#34; &#34;will,&#34; &#34;preliminary,&#34; and similar expressions, and are based on management's current beliefs and expectations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include&#58; (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, and many other factors&#59; (ii) the status, timing, and expected results of the Company&#8217;s clinical trials and planned regulatory submissions, and our expectations regarding our ability to potentially accelerate the timing of any trial or regulatory submission, depend on a number of factors including favorable trial results, patient access, and our ability to manufacture in accordance with CGMP and appropriate chemistry and manufacturing controls&#59; (iii) the Company may change its plans due to unforeseen circumstances, or delays in analyzing and auditing results, and may delay or alter the timeline for future trials, analyses, or public announcements&#59; (iv) the results of scientific research are uncertain and may have little or no value&#59; (v) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship&#59; (vi) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies&#59; and (vii) we may alter the timing and amount of planned expenditures for research and development based on the results of clinical trials and other regulatory developments. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About MIMEDX</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-</font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION&#174; process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">www.mimedx.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Contacts&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investors&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Jack Howarth</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Investor Relations</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">404.360.5681</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">jhowarth&#64;mimedx.com</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Media&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Hilary Dixon </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Corporate &#38; Strategic Communications </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">770.651.9307 </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">hdixon&#64;mimedx.com </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:142%">Selected Unaudited Financial Information</font></div><div style="margin-bottom:5pt;text-align:justify"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MiMedx Group, Inc.</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) Unaudited</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASSETS</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,007&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95,812&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,243&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,423&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,137&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,361&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,350&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,605&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax receivable</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,138&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,045&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,816&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,371&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147,691&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,617&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,273&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,437&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,144&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,623&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,976&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,976&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,750&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,004&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,147&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202,032&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; DEFICIT</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,563&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,765&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,257&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,467&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,073&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,460&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,678&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,470&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,571&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,162&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long term debt, net</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,905&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,697&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,314&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,755&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</font></td><td colspan="6" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101,790&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110,614&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock</font></td><td colspan="6" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,494&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,568&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders' deficit</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,137)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(150)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities, convertible preferred stock, and stockholders&#8217; deficit</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187,147&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202,032&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.1pt;margin-top:0.1pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MiMedx Group, Inc.</font></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) Unaudited</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,165&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,647&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,132&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,383&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,760&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,198&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,401&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,223&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,405&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,449&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,731&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,160&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,599&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,329&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,003&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,270&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investigation, restatement and related</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,062)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,446&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,134&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,038&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,063&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,259&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,402&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,910&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">454&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(410)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,856)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,262)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,600)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,371)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,574)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,844)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,961)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax provision</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,784)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,439)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,108)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,564)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision benefit (expense)</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,277&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,779)</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,466)</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,161)</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,287)</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss available to common stockholders</font></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,276)</font></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,466)</font></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,126)</font></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-bottom:3pt double #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,287)</font></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share - basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.03)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.08)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.12)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.12)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share - diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.03)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.08)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.12)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.12)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding - basic</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110,276,636&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,119,461&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,841,428&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,081,625&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding - diluted</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110,276,636&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,119,461&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,841,428&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,081,625&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.1pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.634%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MiMedx Group, Inc.</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) Unaudited</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities&#58;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,161)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,287)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash flows used in operating activities&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,304&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,783&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,467&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,928&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">454&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of deferred financing costs</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">833&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,441&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash lease expenses</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">480&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accretion of asset retirement obligation</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on fixed asset disposal</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">236&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase (decrease) in cash resulting from changes in&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,820)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,230&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,460)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,254&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,819&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(93)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,682)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,387&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">821&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,794&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,236&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,790&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(518)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,752)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,109)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(514)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(609)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash flows used in operating activities</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,080)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,378)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash&#160;flows from investing activities&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of equipment</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,346)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,421)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments from note receivable</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent application costs</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(200)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(151)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash flows used in investing activities</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,501)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,572)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from financing activities&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from exercise of stock options</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,359&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">298&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock repurchased for tax withholdings on vesting of restricted stock</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,563)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,330)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal payments on finance lease</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing cost</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayment of term loans</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,875)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from term loans</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash flows used in financing activities</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,224)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,930)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net change in cash</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,805)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,880)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, beginning of period</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95,812&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,069&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, end of period</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85,007&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,189&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:162%">Reconciliation of GAAP Net Sales to Adjusted Net Sales and Reconciliation of GAAP Net Income to EBITDA and adjusted EBITDA</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">In addition to our GAAP results, we provide certain non-GAAP metrics including Adjusted Net Sales, Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;) and Adjusted EBITDA. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements. Company management uses these Non-GAAP measurements as aids in monitoring our ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies. Adjusted Net Sales is intended to allow one to understand the trend, if any, in sales and to facilitate comparison of sales amounts in periods that used different revenue recognition methods. EBITDA is intended to provide a measure of the Company&#8217;s operating performance as it eliminates the effects of financing and capital expenditures. EBITDA consists of GAAP net loss excluding&#58; (i) depreciation, (ii) amortization of intangibles, (iii) interest expense, net, and (iv) income tax provision. Adjusted EBITDA is intended to provide a normalized view of EBITDA and our broader business operations that we expect to experience on an ongoing basis by removing certain non-cash items and items that may be irregular, one-time, or non-recurring from EBITDA&#59; most significantly those expenses related to the Audit Committee Investigation and Restatement. This also includes share-based compensation, which is predominantly settled in shares. This enables us to identify underlying trends in our business that could otherwise be masked by such items. Adjusted EBITDA consists of GAAP net loss excluding&#58; (i) depreciation, (ii) amortization of intangibles, (iii) interest expense, (iv) income tax provision, (v) (benefits) costs incurred in connection with the Audit Committee Investigation and Restatement, (vi) the effect of the Company&#8217;s change in revenue recognition on net loss, and (vii) share-based compensation. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">A reconciliation of GAAP net sales to Adjusted Net Sales appears in the table below (in thousands)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.044%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.044%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,165&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,647&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128,132&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,383&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of change in revenue recognition</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(313)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,706)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(611)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,201)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted net sales</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,852&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,941&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127,521&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,182&#160;</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:162%">A reconciliation of GAAP net loss to EBITDA and Adjusted EBITDA appears in the table below (in thousands)&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.564%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.364%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</font></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,779)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,466)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,161)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="5" style="border-top:1pt solid #000000;padding:2px 1.02pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,287)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net margin</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(2.6)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(15.8)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(7.9)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(11.5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP Adjustments&#58;</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,306&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,422&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,467&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,928&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">271&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">454&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,371&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,574&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,844&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,961&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision (benefit) expense, net</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,277)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EBITDA</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,108&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,172)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,343)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,133)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EBITDA margin</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.6&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(7.8)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(3.4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(14.0)</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Non-GAAP Adjustments</font></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Benefits) costs incurred in connection with Audit Committee Investigation and Restatement</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,062)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,446&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,134&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,038&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of change in revenue recognition</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(269)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,467)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(525)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,333)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,060&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,434&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,304&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,783&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,837&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,241&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,570&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,355&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA margin</font></td><td colspan="6" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.2&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">19.1&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="6" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5.9&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">11.6&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA, % of Adjusted Net Sales</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.2&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">19.7&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5.9&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">12.2&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">%</font></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mdxg-20210803.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6a9cdaba-539b-4768-8d5e-c492b3a0428b,g:0f138a66-3c41-4a4d-a286-37b9255723ba-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mdxg="http://mimedx.com/20210803" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://mimedx.com/20210803">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20210803_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mdxg-20210803_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://mimedx.com/role/CoverPageDocument">
        <link:definition>0001001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mdxg-20210803_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6a9cdaba-539b-4768-8d5e-c492b3a0428b,g:0f138a66-3c41-4a4d-a286-37b9255723ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_ee7ce580-3b05-4f52-b6dd-5e769068ce4b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cc7bf024-b706-4182-adf3-c6aca98bebef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fe1f317b-e406-4458-b8e0-7500ee225ad5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_14edb65d-28b4-44e4-bb98-7b710221883f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0800acdd-9535-4eaa-b0a0-bd6c17ca1abd_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9d104de0-24d8-4d6c-a598-353557ac8a09_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_868010ed-09c0-4d88-a62b-026e50d1fcb6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ad4264d5-d635-43ae-9308-4f19f946fb55_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5846991f-aa50-427a-b4d3-bec9370be8f4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_74534322-00a8-4679-9fb6-28ba8c53dbad_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_403f47f3-bdd4-4d3e-b51b-654429a727f3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d1e79d0b-be0f-4805-8c9d-4254ca7f11a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_84224c44-fa15-456a-bc7f-5bebfe2a5543_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_85143706-5bbc-476d-a9bd-2acaa162357d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_a8673407-0e85-421f-8515-da925a4a514d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_a94e57be-ff5a-4df3-a1aa-42a9cd0ff742_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_083da94f-06f6-48d3-a29d-ca8567bc19e3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c6aef5cf-a7ce-4d1c-b1ed-109b0178b344_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3d692cd1-8328-44b5-9690-b6543142a1e2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_aa6126dc-b2ce-44db-bb86-17c1a6fadd11_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a7224f65-d229-45d6-b57a-d65946e3c263_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_144adca8-eaef-430e-883e-911db54a6176_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e730017f-5036-455e-becf-7d96cd020b59_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mdxg-20210803_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6a9cdaba-539b-4768-8d5e-c492b3a0428b,g:0f138a66-3c41-4a4d-a286-37b9255723ba-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://mimedx.com/role/CoverPageDocument" xlink:type="simple" xlink:href="mdxg-20210803.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://mimedx.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_645dd43e-64c8-4c93-bc98-41541a3e6182" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_DocumentType_645dd43e-64c8-4c93-bc98-41541a3e6182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_75002a3b-cc24-4510-a052-3149566f30a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_DocumentPeriodEndDate_75002a3b-cc24-4510-a052-3149566f30a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cd74f4d9-32ae-4a6e-9445-1df74fea8c62" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityRegistrantName_cd74f4d9-32ae-4a6e-9445-1df74fea8c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2b51d7e8-cd96-43ff-8517-840d82b8a23c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2b51d7e8-cd96-43ff-8517-840d82b8a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ad5f4846-955a-42d4-9f9d-92668c62ed15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityFileNumber_ad5f4846-955a-42d4-9f9d-92668c62ed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_54bd2144-e8c8-4b29-b6fb-0e95ff2eeec8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityTaxIdentificationNumber_54bd2144-e8c8-4b29-b6fb-0e95ff2eeec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5baa5e83-beff-4fda-8f48-1f865c71b51f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityAddressAddressLine1_5baa5e83-beff-4fda-8f48-1f865c71b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f184808-440f-4a66-ba02-ba5226eca4cd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityAddressCityOrTown_8f184808-440f-4a66-ba02-ba5226eca4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_13347e0b-59e5-45b3-b944-e153222ee8e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityAddressStateOrProvince_13347e0b-59e5-45b3-b944-e153222ee8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e6450048-2901-4e8f-aa55-b38e1ceab70e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityAddressPostalZipCode_e6450048-2901-4e8f-aa55-b38e1ceab70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e251d230-2cb3-4bcc-b6c6-415db960e77f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_CityAreaCode_e251d230-2cb3-4bcc-b6c6-415db960e77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_793508bf-439b-40ae-ba24-7887757cb25f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_LocalPhoneNumber_793508bf-439b-40ae-ba24-7887757cb25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_0f8f7dc9-16b3-4c80-ae0a-df95b12c8a00" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_WrittenCommunications_0f8f7dc9-16b3-4c80-ae0a-df95b12c8a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d65042c7-3feb-45ee-903e-6eacd72d0324" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_SolicitingMaterial_d65042c7-3feb-45ee-903e-6eacd72d0324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a1750c85-fc98-4b86-870a-26975ea44f4e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_PreCommencementTenderOffer_a1750c85-fc98-4b86-870a-26975ea44f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_4044e816-0c00-4fb6-b24f-49beb9460a8f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_4044e816-0c00-4fb6-b24f-49beb9460a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6b855dca-17ac-4786-986b-ac4bba7b92c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_Security12bTitle_6b855dca-17ac-4786-986b-ac4bba7b92c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1c44325b-8f1d-4551-a392-efdf33c8ccdf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_TradingSymbol_1c44325b-8f1d-4551-a392-efdf33c8ccdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c51c38f3-05a8-474d-8591-5421c3882354" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_SecurityExchangeName_c51c38f3-05a8-474d-8591-5421c3882354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9c8d3c9b-d99a-46b5-8d6c-1a467f9b0a42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityEmergingGrowthCompany_9c8d3c9b-d99a-46b5-8d6c-1a467f9b0a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_172a2c0e-d3be-48e1-af68-5a02eab06afe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_EntityCentralIndexKey_172a2c0e-d3be-48e1-af68-5a02eab06afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_24af7316-8a4b-491f-a2bc-c76a82639f42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8ac79f9d-3198-46f4-9097-2279b643e73d" xlink:to="loc_dei_AmendmentFlag_24af7316-8a4b-491f-a2bc-c76a82639f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>mdxg-20210803_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mdxg-20210803.xsd" xlink:type="simple"/>
    <context id="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001376339</identifier>
        </entity>
        <period>
            <startDate>2021-08-03</startDate>
            <endDate>2021-08-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N180L2ZyYWc6YjQ0MGNiNmQzN2QzNDY1MDhkNTRiZjJmZmUxMDE0YmEvdGFibGU6Y2E4Mzc5MWYyOGE3NGFiNWJmYTY1MzhkNzI2MGUxNmYvdGFibGVyYW5nZTpjYTgzNzkxZjI4YTc0YWI1YmZhNjUzOGQ3MjYwZTE2Zl8yLTEtMS0xLTA_edc3964c-9475-41d5-8ae7-dead79b9d7bd">0001376339</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N180L2ZyYWc6YjQ0MGNiNmQzN2QzNDY1MDhkNTRiZjJmZmUxMDE0YmEvdGFibGU6Y2E4Mzc5MWYyOGE3NGFiNWJmYTY1MzhkNzI2MGUxNmYvdGFibGVyYW5nZTpjYTgzNzkxZjI4YTc0YWI1YmZhNjUzOGQ3MjYwZTE2Zl80LTEtMS0xLTA_c49f3310-c943-45b0-8c87-3c3549b23b7e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkx_73bb1c1b-e4de-4f5d-996a-5eb0c44d276c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl8yNjY_010548d7-ba6e-48ce-ae41-21374672879f">2021-08-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDky_7f572413-0523-48f3-ac5a-c4b2cbfbe926">MIMEDX GROUP, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTAtMS0xLTA_d5afe9d5-d07b-43c1-b5c0-75f032fdb24b">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTItMS0xLTA_e1fe21ae-48c9-4ba8-980d-4a5fe94199ff">001-35887</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZTZiMWE2NTg3MGFhNDhlMjliY2IxNDUzMzJlMmFhYjEvdGFibGVyYW5nZTplNmIxYTY1ODcwYWE0OGUyOWJjYjE0NTMzMmUyYWFiMV8wLTQtMS0xLTA_aac5f528-cc41-497b-86dc-a27c18e4ff45">26-2792552</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkz_a2c83742-9542-4cb0-a8d5-752cec542897">1775 West Oak Commons Ct., NE</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk0_f47252cc-cc85-49dd-8c13-e3c279a0c5d3">Marietta</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk1_d91af8b0-dfd8-4403-8f66-8175854f754f">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk2_4950b0fa-5422-4845-875d-550248d22072">30062</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk3_a7df9d3f-8e34-40cb-9219-3bbff4c70848">770</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDk4_2e765f91-7713-41fd-a74d-77c488d11e21">651-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18wLTAtMS0xLTA_4821b00f-ddcc-40b7-a49d-d42678786f45">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18xLTAtMS0xLTA_e9ea04ae-6507-4eae-824c-cb0c12782014">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18yLTAtMS0xLTA_8ba905f4-ed73-47f5-bdd9-2f4fadd5a0a6">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZDc4M2ViNGQ3NzliNDY5MDk3YzE4OTExZTI0NDEyMDcvdGFibGVyYW5nZTpkNzgzZWI0ZDc3OWI0NjkwOTdjMTg5MTFlMjQ0MTIwN18zLTAtMS0xLTA_c4442e03-b4f0-4170-ba26-12a446b9192a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTAtMS0xLTA_e9e2d84c-6f36-4dcc-803a-333acfc8d647">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTItMS0xLTA_aee54f97-3394-4b8a-ba97-b75896e37427">MDXG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGFibGU6ZWQxMDI3MmFiYmQwNGJjNGJjOWNmMTQ2YWVjN2Q3ODMvdGFibGVyYW5nZTplZDEwMjcyYWJiZDA0YmM0YmM5Y2YxNDZhZWM3ZDc4M18xLTQtMS0xLTA_56226558-229c-4708-a1df-ceb04b331dfa">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxOWQ2Y2ZjMzg5YzRjZjNiMTkyOWEyZWFlZGU3ZjY3L3NlYzowMTlkNmNmYzM4OWM0Y2YzYjE5MjlhMmVhZWRlN2Y2N18xL2ZyYWc6MmY1YWUzM2QzNmZmNGIzMjhhMmRmODlhODY2YThkMmYvdGV4dHJlZ2lvbjoyZjVhZTMzZDM2ZmY0YjMyOGEyZGY4OWE4NjZhOGQyZl80MDkw_f3aaabb2-0ec0-4851-a083-d56a682e01d4">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140437134797944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Aug. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  03,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MIMEDX GROUP, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2792552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1775 West Oak Commons Ct., NE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marietta<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-9100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MDXG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001376339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M 0  , (   \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y
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M';W.]/YA\JBMM,ZME'L/KV3+,?#X6<L?4$L#!!0    ( %J+ U,D'INBK0
M /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2
MY0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D
M1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#
M='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#B
MR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !:BP-399!Y
MDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE
M+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WU
MV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R
M;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$
M7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@
M9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!
M3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+
M 0(4 Q0    ( %J+ U,'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 6HL#4VJ:/.3N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M6HL#4YE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !:BP-3U1 VMCX$  !%$   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M6HL#4Y^@&_"Q @  X@P   T              ( !@0P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " !:BP-3EXJ[',     3 @  "P              @ %=
M#P  7W)E;',O+G)E;'-02P$"% ,4    " !:BP-3VU\'[3D!   P @  #P
M            @ %&$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 6HL#
M4R0>FZ*M    ^ $  !H              ( !K!$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ 6HL#4V60>9(9 0  SP,  !,
M         ( !D1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  VQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mdxg-20210803.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mimedx.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mdxg-20210803.htm">mdxg-20210803.htm</File>
    <File>a20210803mdxg2q2021pressre.htm</File>
    <File>mdxg-20210803.xsd</File>
    <File>mdxg-20210803_lab.xml</File>
    <File>mdxg-20210803_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mdxg-20210803.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "mdxg-20210803.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mdxg-20210803_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mdxg-20210803_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mdxg-20210803.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mdxg",
   "nsuri": "http://mimedx.com/20210803",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20210803.htm",
      "contextRef": "iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page Document",
     "role": "http://mimedx.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mdxg-20210803.htm",
      "contextRef": "iffc02be14c8e4d58ac67a7b7a3e24cec_D20210803-20210803",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://mimedx.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001376339-21-000095-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001376339-21-000095-xbrl.zip
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M5BJ^I\<\D#?A":WP!S58\8(7!5%\\J-%_SO%.\=]/I3!_<G?SN&M7BS_9B2
MC>-$Q+*O'DCD?\6)[<#@].>=FGD#W@]D*(J5V*X+T[_X]^^7;R^O6;=KVM-S
M+\VZ-$</8"SBM4VR]6"2[8>3=!#&'R\_7KS[-SL+PR@+/9&P*^%%H<_^F?$8
M9J.(8N[LIV%NF?8TU%]Z103VSR,1\Q0IG<,ZWLN0AY[D ?LJDBQ(D[6L908]
MO@A.[0("--*)3.%QKP(I/D#J)Y&R*QX MB]#% Z)8$[[9Y9&[*=6QW08S"4
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MKE$CHS IJM1\'5>I.8_R*C7FK(M4TRL=1%1)J;B&]6-4%961B*FJ5>@)%O4
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ME:"ALOT,US'YI)HW!CZIE4K9A_9A.+!L)S7^'_8AH/7DU&#0D',>/ O## 3
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M^"M##.8I]O!0+.2PE\4)+=' HQS?A"*84:KD61]FB:GQI2VO&734RV3@%_0
M6@AFHA*_)L%QCY:,SI!JGTOA9]4_>9SKCIPUD*,"'DM;)#.MD63*'$DP6$[2
M)-<+9&RI3,<20FG[[D%NL)K>Q)JY$X3<*3H;TZ=*I\)VQ[F4H>0MF ,07Y(?
M<)MC^(PU^P-ZFR7#%%&4)$EIH&3ZK +X!1Z G3+EQO;4')58:*"O<'NL:I+)
M"3I).6^@#C'YC]+&0J5T:!^ 3^*PE+&'%V'-,H!EC?<GKB9):?C\Q?=</IR/
M#Q. !@WOG[+XP$+DWP!0*'''DA\SI=3O1^[10S7/@8KP?!/PX^0\(XFD$8W"
MG_K\8^=[QZREV9[S60^LU#S3L7:F8+Z!()&D4 )DI*X ^3XEGS(0.8%4.F26
M* %633%JG[/GC P H^"O@L\GL@PNH&T(E($<FH]:="1/%-UC$BBL :1Z2E8+
M=34']2I2C%_ ;]I04.)AB"<K1@%E;Q+[ 4U/C*<\5V $!"O4VB8?[TD \XWT
M0&2#B%*G<T%.8)8Q<D$/MRO(,.A'8*HI40,B@5R,/. $@_JJ6;NR)?+Y<R]+
M%1MY VR+[@'K8%294Q+['18%+SP47 WP,5['S-1C'4[?V7 ZB#20NR,Y4D82
MT.*-0),:DT'4J5DB[L*@D4,RW-$"!9V1%AF1TY3B3W%/EH!2CI)O((>10"?*
MV&1_%KWII^T=<E949LU#KLJ-=\4L^;F(XH[:B<M'&C/64("#Y4\E[2"1?_GC
MZ^7G3[_\:+?!W\['HPF)X2B([MEY[DO_%D4^4]W8V!=U6!S-H:G;'Z?,X=)3
MI'-$C+X]&A*P5)! 8T6CUJO6/A$6XT-$ YY0@E* T0QU8N@NFB3+C5_ =)DX
MRFX&BM%S$RP_*X39.2J@ B96X3U.)V^7-BM!)"EE>0O,F^[8OMYTD'P;&=L[
MF+&PA^%[S+S'XA(+[XS7"@K3VW^[.O?9?/!W[GUCO^.QPW2P7S,OH,Z^%I[G
M?LV_835,MP76TH([K@O-_(7E^G\&BI)^^;'5.'TLX ].,GS$-)4]E J_2RKE
M\$Y^!_-DOZ9^'L6CB"*VO_SH=D[9%99#$.!%44 B"\?!I/U:5KMMF:VF;79=
MJ[VYJ;]T>I>/!/9 6#QGJFX$O(]!^I3,62WG1;^GW]O>>^OB*^<Y!=AP5&TE
MM:TW.1([.?MZ.?%6*RZON;Q]</#AJ6E(ME093]IV'*^4RD9BB3T^2L1)\>/4
MEPGFSIW(D!!,+YT^1LR#NJF$)W5[,FO34C//R^SG7\YOFW2K*&PY=:_5-%MM
M>^YM(/NE[MEFTVDL^>;\R=J.:;5::Y^L97:Z[0V P&JZ&K#=2F_.;!'A-*JT
MRL#0IXA?N+CP(Z%,Q84_2O!+OK/?L**E 5+8FVR!U6>1<RHOO.4![8M?#81(
MD[U>]^S*T4>TXQME,(:?O)KHW>>7NDJMX66Z!,^J.3Z4OA^(:17X",XO#-&B
MA$"5[=*M3/#Q$<^UUI&N,V[+)QEW&;_6#/S6JU_1V=75Q?75W%+W,ZN;5ZQD
MO\Z"ZHL5SZ\);HH=4IXDXN%FSWRH;087ZP)WVVRW=Q7<\RJN+-#9;$\HJTJ[
MC[UHV-%I&I95O;O19AK!O!SR\2!UPCZ)._8U&O)P_XE@K0OJ-HV.7;VGT &(
MM#./\IV+(I,80<*Z]NE<Z.Q9^TFW;3@-W?BU"J2:1L-9$5+UX@U,9 @QY[LN
MS&!;ANUN1Q?N'Z3<ULNWK=UA9O@2BQ&7DQ*Y=>$)UW";EF:)YP'5-%I6]=ZU
M!\ 1EZ&'I:I3_KUD/-6%+4A5=#1?5(*4U=",48+(9W6.<BHV58$O5HAJ[Q U
M@(/9VC+;U *0H)?;+V^ V=W=#<E=1W2T9TFVVN>>NXVVT>I6)X87VXBH%9!;
MEM&R%VX#?[!;+U_B:"3PL#T5R?@K4R>_:A4[ \O&:>O8615(V49CU<!*O=CC
M*_[&\\U4,0=U55VXPC7L1D,S115 M;803]YAGL!SS%B7K"Z<8'>-;GO;SL[!
M0*I>O' 9ICR\D9CEKCR96EE.3:.M@\I5 -4R+&M%95HS+U\%SRI[]WN!9=?6
M7D2E7(67#R/OL(I0\:YG.&'!@,2>++U*XM5TE-<=86.I#/5I,:T:Q*0Z;7"V
M%HY)K0B2]:;^:;*L'5DZEF-8;O4TP@V092[IBR\4TVNJPZ-K3*N?,=N-I_)7
M_6:]U-V'R[.WEQ\NKR\OK@QV_OG3ORZ^7E^^_7#!OGR]>'_Q]>O%.W9U_?G\
M'P8[^Y3__/WSAW<77Z_R&LSLW<7[R_/+:WT"8/,'+@*I:O2JHK7ZU,6+I"B/
M^/V3*39[R_J[D&>_KAVC9FL[OIY&_K87TC':+9T'-2VXXDSXJHM#F$S74]GS
M6(5C&TY3IY)7<F*-1NOE]X;W@"_JEDINMPU+YTM4BG1:P!,K;I#4R_N;SIDM
MN1>'DSC;:F\[W[PF@&RT-6O-S9M=BK7V.%C9!)=L@41JG3N[#(R[AMU:.!Z\
MX=39'=[C_A!A@P@1#YDO>O7*F6VTC>ZJQ^0.PP:DI'Z=,_O(!CQ V\\U7'O;
M*;4U 62[J7-('ME^J[!4+7>P;<LVVMWJ7L+VK,):8\'&(U?5!=^+V(WMW67F
M\RBD:2 5C&+1%^#184W@R/NVF"OW1(+!3A-,US$:W:7H9<-I'/6"LFTT6]5#
M40>?N*)T++'A( JPW?C?P*_K2T_6QJL[:F/AI%?:H7L22';36AI$=62)DMEI
MP*+F*B_5P[+,0$5&UW-LM*&TRUT'K\Y#K5MZM*;; Z+;7<F??DT-<]Y4Z]:6
M7\-O+-L#JK-C':>*]W0'IGWNP-2P3:?;W$"C(*<S_Z-+-PJ"9;:7&_;I>VWJ
M:K;N43OM]3<UTH#5@-6 W21@F]7>G.ER-CI5G.X=:J>U3,^PO5ODG)YA5RG\
M!\MN)5AIZ/-(Q _ZC>\C!+;8/<RQU[$=ND-0NQ[$0K"/\-P@81= 0SY[U#1L
M!3>V=O"ZDM\K0&OM3>H6]F5W"&13/=XVM8-:-XA9Z^"^N@%%D]%J9%2O+81/
M C[%@R<R5@Z^QL0>AT!;'<->X+"DKENB:>K9539=H[7X;I"F*4U33VPQ.B"H
M%M^JT42EB>JIO,>FX7:J'Y0]]%+SYU%"I;2?-@=KELIN.T9[U2/"^E" JLMA
M=_7)VG5XG([1L%;L2:,AF=?$<'1M^#)$?HNC)&&C..I7RIK=?R.@V01FVD$/
MN$XP;@",&UT-X\T>I6H:;5<?L-_LD8RV82]@#*ZMGFIC/?54UXG6&HU:+PV>
MIQ^$-^.Z5CM8&72?1JU7T;,K$<#%&X/=B! (): S']P?RE F:4R)MG4Y+=5T
MC6:WNMEQP$>FW+;A.AI252R KF%9NK9>E7!/PW"V4 !LAT7O97@KDE3>4'*@
MP6+X(\\;)"%,YQP>9-+M,?Z/',-J.?JLZK,-.QNZ=5T596[8[K9K\^P%H)RV
M8;DKQMGK)7>_BD3PV!N0E/7%K0@B:I)<%TG; $&K39(JK&$X36WE5MJJ:UC5
MDRT.&% -HVMK&[<$D+-A!)/X+YFXF"L@'_97/92\ <?>=O7->H!Q@9K!&HQ/
M[,!MVW:N!1B;C16U8EVW&H(H.8PRYD<-NU)Q*;V]N@QPFT:GV=+@W11XVX93
M+2*GP;M4W;FNT;(V)!TVVVAU[_=H]<YOE>V'5.">0Y$74*M^!T>VX;9MO=OP
MW)9,L]W00'H.2)V&!M)S9K#1;2W/;O42K*I?QH)2M1;^\)&[/3ZI!P"[&H K
M2FL-P&VQ<+V"61_PX$M/]*-8,!EZT5"PE'_'HS"W,JG6,;D./JS1[E0R?G2(
M8!GP=HR&6TGD:_ N1;V685L=#=^-*=N&T6QM2#S42YM<SM @H%U"T9<I.\I]
MA?F K)F1H;?"U\)]6^S\4@\(-K6_NG*^LM/6S5)+$,'Z>+-VOV=B?94V&A:;
M01D[ X;Y%8.:<SA@I98B1 \$$&LW&04=J?8BEO[VNN%H2CUL2@6?M+5(TH6F
M5$VIVW/OJ^TZ:5+5I+I=4G4-IU/)7]M45[&-)0N]7#M?_<V#:^);N%.,WW(9
M4.^S-()U#8=1R,JM29?UMPY,INZ9V 2IV5Z/+?J".ER3U"Z3U/K<&TU2FJ0*
MX\YV-$UIFMI-AV$1GV!-E07WQ%8^E&_6U"<8B7CL"@QX+-@QZ_%$>G-\@7H)
MO#V39Y9IO=1FJT;WUE>$Z*Z4=Z7171-TVR^5>*W1O?45K8;NPS%&?!ED,RHX
M:@K>^HJT.7)PZ-;FR"&A6YLC&MT+F2,;VAS?3 AH[T>MEPWX)_TA?,9A-OQ&
M3-F!"8NR-$EYB"N:%Z&:D1^^)_G?%N[0&BU7%ZVN BZK8]AVUVBTMEW%<$_
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MS(F7RY"E@RB#,?SD%?LCY)DO'SJ]%6, <VUSQUY'I8L=@MJ5_,X^PE.#A%T
M!?GL[UDHF&L9RX!M3T(GS[@ICW)2YZ)XV5I7.X1_QW+LC1<2.S2(6C5F'M(A
M?=0AK!]'0Q:-NZ-P#_P*\!BJMV)_L?)TJWRR7E6<GRGDHS?\]Z+P@\[PJ ?"
M*Y^&.@#)=.;_)TM2Y:ND$8N%%X6># 16FE>YJ' 5?WL3#92APP-V_RI*:,?S
M0]S=-06N<*OQN,<1"5XTQ&*?U!&S+MN,;<.UMMU0<$\ U>ZLV)JY9JSQ3HQ
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M["WZNA?Y]_"?03H,WOQ_4$L#!!0    ( %J+ U/L?<B@%QD  "J2   1
M;61X9RTR,#(Q,#@P,RYH=&WM7>E7V\BR_W[_BGZ>]^XEYR"CU9*<A'L8;!AG
M8CL!,XS]):>E;F$96?)H 9N__E6U).\0LA @9,[)8%N]5%=7_6KI16_^.QT'
MY(K'B1^%;RM*5:Z0_^Z_^1])^OOWD_>D$;G9F(<I.8PY33DCUWXZ).>,)Y?$
MBZ,Q.8_B2_^*2I*H<QA-9K%_,4R)*JO*VL.X7J.VRZA#)4.S'4DW:Y9D,8-+
MKFZKCD9E7;6<W8NZ["F:16LU27-U1=*ISB2J6O#5=&S5,$Q5<^@NJ\N*S6JN
MYVJ6[>JNISF*K=I4Y90S;GHU$[L=IC Z&&&8U!GWWU:&:3JI[^U-G3BH)MRM
M7D17>_!@#\B5)5F1-*52%/>GJ00EYE6NKZ_G-?PP\$..#-I+8QHF7A2/:0H,
MA'840Y*MU796VA!=1_'%9QM1);6V:&1[&U!26VJH+#Y-_)7RUUI16E;V_FZ_
M/W6'?$PE/TQ2&KI\7@N:N=Q63[%M>T\\+8MNE%RB2-;V\+%#DT7+\-2_H_P:
M);?3@-,I"M4#&EZ\K?!0.CNMP#1SRO;?C'E*"5:5^#^9?_6V<AB%*0BOU)M-
MH&TW__:VDO)INB>:VMO_U[_^]2;UTX#OC]GT0D*QE2U9>[.7__AF+V_:B=AL
M_PWSKTB2S@+^ML+\9!+063V,0@X$^-,Z%N1Q_M%GC(?B(SSO@ ;%OIOW/TU/
MN/>VXGN>*ZL.5W37XCHS+.K63&HZ)M6XJKO<_=0H29G35"$A'6/7W*\W0Z!O
M=@C#B6G0"AF?_LEG%>(S:)II?\V<1G3U7CVYZFOMC(V:5X-C>]0='4R[YQ_5
MOCH8M6\NC/[-R6@PZOCMWN6L>]Z<#<Z/@L'QF388];7W6B?HWT37[5YPV1EW
MQOV;MMX];\M]M7_3'S6-]B@8ML=_#0?G)T$'6NPHEOQ>'<SZYVZM/_HHMX\[
M?F?\\::CPK]&7VDWAI>=WHD_&+T;#\9GTW:C*??'S2MV?.0[QV>UOMK4VS>N
MT3[OS[K'3:T#OW?.WXW[/:A[ W5O6FK[^&P*E!1U_H*^C'#0FXSZO8N;SLWE
M=#!JZ?V>*_?/6TI_/!AV1F<WW>./6GO4OQ[TFNH@L&;O>\VT?2I/W_<./G'F
M:G9-=R5;-PU)5Y@A692;$H.)-&W'9J;#*OLR*(UFUC3-?K.W,I\/.;T'@+D,
M<?<HH!>_IO5STRHO3RL8$T_3%%ER;5V3=,.1)<NU3# FFJ';#A@/$S36HT'"
M-V9T;U5Y8^[QF ,P)5LP!T&NG@@HA3DG A_K*2#-VTKBCR<!HIGX;1BC2*S
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MP5=7MRRF*%Q5*OLU0Y%L"%J>,C3^P)UQHRR!N&WV2$,Z''+WDJ1#3NAD$D<
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M'T8B*9HE7)2"H1:;^O"&=U\D2O-;:E%=1%_!##L7U^HC)H0P-G@2\RL_@7J
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M3T!WH=8%Q9?B()RXV$L6L@QU+/#Q/3G(=2$:RU (CEVVT$PA5<S'K3'S'8X
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M#;UU;R_,H[,7JV>2Q7]!/WOQ?U!+ P04    " !:BP-3ZO*:H:H&  !^,0
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MV'0\\F$0(OH[060;?:?$R7G=M*;\N[CJBVJ0/.W14]ZC.L65@PHHY46!+%-
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M^S>+)^*=I0-'>W<GNI?N@?VCO?\#4$L! A0#%     @ 6HL#4PZX;]L0.P
M,4$# !X              ( !     &$R,#(Q,#@P,VUD>&<R<3(P,C%P<F5S
M<W)E+FAT;5!+ 0(4 Q0    ( %J+ U/L?<B@%QD  "J2   1
M  "  4P[  !M9'AG+3(P,C$P.# S+FAT;5!+ 0(4 Q0    ( %J+ U.0?#2F
M>@(  (X'   1              "  9)4  !M9'AG+3(P,C$P.# S+GAS9%!+
M 0(4 Q0    ( %J+ U.,5;4!80H  -->   5              "  3M7  !M
M9'AG+3(P,C$P.# S7VQA8BYX;6Q02P$"% ,4    " !:BP-3ZO*:H:H&  !^
M,0  %0              @ '/80  ;61X9RTR,#(Q,#@P,U]P<F4N>&UL4$L%
3!@     %  4 4 $  *QH      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
